Literature DB >> 19130884

Paradoxical delay in the onset of disease caused by super-long CAG repeat expansions in R6/2 mice.

A Jennifer Morton1, Dervila Glynn, Wendy Leavens, Zhiguang Zheng, Richard L M Faull, Jeremy N Skepper, James M Wight.   

Abstract

Huntington's disease (HD) is caused by an expanded CAG repeat in the HD gene. The pathological threshold for expansion in HD is around 36 CAG repeats, although 'super-long' expansions are found in brains of HD patients. We examined the effect of varying the CAG repeat length (from 170 to 450) on behavior and neuropathology of R6/2 mice. Unexpectedly, we found that increasing the repeat length delayed onset of disease and prolonged survival, from around 4 months to over 18 months in mice with the longest repeats. The delay in onset correlated with a delayed appearance of neuronal intranuclear inclusions (NIIs). However, super-long CAG repeats are not neuroprotective. Mice carrying 2 copies of the mutant transgene die earlier than those carrying a single copy. Furthermore, neurodegeneration is present in super-long repeat length mice at mid-stage disease, whereas little neurodegeneration is seen in mice with shorter CAG repeats until end stage. Expanding the CAG repeat beyond the range where NII formation is the dominant pathology has unmasked a slowly progressing neurological phenotype in R6/2 mice with brain pathology, including the identification of a novel form of inclusion, that more closely resembles that seen in adult onset cases of HD. This mouse may represent a better model for adult-onset HD than R6/2 mice with shorter repeats.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19130884     DOI: 10.1016/j.nbd.2008.11.015

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  56 in total

1.  Disruption of the nuclear membrane by perinuclear inclusions of mutant huntingtin causes cell-cycle re-entry and striatal cell death in mouse and cell models of Huntington's disease.

Authors:  Kuan-Yu Liu; Yu-Chiau Shyu; Brett A Barbaro; Yuan-Ta Lin; Yijuang Chern; Leslie Michels Thompson; Che-Kun James Shen; J Lawrence Marsh
Journal:  Hum Mol Genet       Date:  2014-11-14       Impact factor: 6.150

2.  A critical window of CAG repeat-length correlates with phenotype severity in the R6/2 mouse model of Huntington's disease.

Authors:  Damian M Cummings; Yasaman Alaghband; Miriam A Hickey; Prasad R Joshi; S Candice Hong; Chunni Zhu; Timothy K Ando; Véronique M André; Carlos Cepeda; Joseph B Watson; Michael S Levine
Journal:  J Neurophysiol       Date:  2011-11-09       Impact factor: 2.714

3.  Early autophagic response in a novel knock-in model of Huntington disease.

Authors:  Mary Y Heng; Duy K Duong; Roger L Albin; Sara J Tallaksen-Greene; Jesse M Hunter; Mathieu J Lesort; Alex Osmand; Henry L Paulson; Peter J Detloff
Journal:  Hum Mol Genet       Date:  2010-07-08       Impact factor: 6.150

Review 4.  Aggregation formation in the polyglutamine diseases: protection at a cost?

Authors:  Tiffany W Todd; Janghoo Lim
Journal:  Mol Cells       Date:  2013-06-19       Impact factor: 5.034

Review 5.  Huntington's disease: can mice lead the way to treatment?

Authors:  Zachary R Crook; David Housman
Journal:  Neuron       Date:  2011-02-10       Impact factor: 17.173

6.  Detection of axonal degeneration in a mouse model of Huntington's disease: comparison between diffusion tensor imaging and anomalous diffusion metrics.

Authors:  Rodolfo G Gatto; Allen Q Ye; Luis Colon-Perez; Thomas H Mareci; Anna Lysakowski; Steven D Price; Scott T Brady; Muge Karaman; Gerardo Morfini; Richard L Magin
Journal:  MAGMA       Date:  2019-02-15       Impact factor: 2.310

7.  The group 2 metabotropic glutamate receptor agonist LY379268 rescues neuronal, neurochemical and motor abnormalities in R6/2 Huntington's disease mice.

Authors:  A Reiner; D C Lafferty; H B Wang; N Del Mar; Y P Deng
Journal:  Neurobiol Dis       Date:  2012-03-27       Impact factor: 5.996

8.  A restricted population of CB1 cannabinoid receptors with neuroprotective activity.

Authors:  Anna Chiarlone; Luigi Bellocchio; Cristina Blázquez; Eva Resel; Edgar Soria-Gómez; Astrid Cannich; José J Ferrero; Onintza Sagredo; Cristina Benito; Julián Romero; José Sánchez-Prieto; Beat Lutz; Javier Fernández-Ruiz; Ismael Galve-Roperh; Manuel Guzmán
Journal:  Proc Natl Acad Sci U S A       Date:  2014-05-19       Impact factor: 11.205

9.  Comprehensive behavioral testing in the R6/2 mouse model of Huntington's disease shows no benefit from CoQ10 or minocycline.

Authors:  Liliana B Menalled; Monica Patry; Natalie Ragland; Phillip A S Lowden; Jennifer Goodman; Jennie Minnich; Benjamin Zahasky; Larry Park; Janet Leeds; David Howland; Ethan Signer; Allan J Tobin; Daniela Brunner
Journal:  PLoS One       Date:  2010-03-22       Impact factor: 3.240

10.  Rescuing the Corticostriatal Synaptic Disconnection in the R6/2 Mouse Model of Huntington's Disease: Exercise, Adenosine Receptors and Ampakines.

Authors:  Carlos Cepeda; Damian M Cummings; Miriam A Hickey; Max Kleiman-Weiner; Jane Y Chen; Joseph B Watson; Michael S Levine
Journal:  PLoS Curr       Date:  2010-09-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.